74: Valnoctamide treatment of cytomegalovirus infected newborn mice blocks brain infection and rescues aberrant postnatal neurobehavioral ontogeny

2017 ◽  
Vol 216 (1) ◽  
pp. S53-S54
Author(s):  
Sara Ornaghi ◽  
Patrizia Vergani ◽  
Michael J. Paidas ◽  
Anthony N. van den Pol
2008 ◽  
Vol 82 (24) ◽  
pp. 12172-12180 ◽  
Author(s):  
Đurđica Cekinović ◽  
Mijo Golemac ◽  
Ester Pernjak Pugel ◽  
Jelena Tomac ◽  
Luka Čičin-Šain ◽  
...  

ABSTRACT Human cytomegalovirus (HCMV) is the most frequent cause of congenital viral infections in humans and frequently leads to long-term central nervous system (CNS) abnormalities that include learning disabilities, microcephaly, and hearing loss. The pathogenesis of the CNS infection has not been fully elucidated and may arise as a result of direct damage of CMV-infected neurons or indirectly secondary to inflammatory response to infection. We used a recently established model of mouse CMV (MCMV) infection in newborn mice to analyze the contribution of humoral immunity to virus clearance from the brain. In brains of MCMV-infected newborn mice treated with immune serum, the titer of infectious virus was reduced below detection limit, whereas in the brains of mice receiving control (nonimmune) serum significant amounts of virus were recovered. Moreover, histopathological and immunohistological analyses revealed significantly less CNS inflammation in mice treated with immune serum. Treatment with MCMV-specific monoclonal antibodies also resulted in the reduction of virus titer in the brain. Recipients of control serum or irrelevant antibodies had more viral foci, marked mononuclear cell infiltrates, and prominent glial nodules in their brains than mice treated with immune serum or MCMV-specific antibodies. In conclusion, our data indicate that virus-specific antibodies have a protective role in the development of CNS pathology in MCMV-infected newborn mice, suggesting that antiviral antibodies may be an important component of protective immunological responses during CMV infection of the developing CNS.


Virology ◽  
2000 ◽  
Vol 266 (1) ◽  
pp. 52-65 ◽  
Author(s):  
K. Gottlieb ◽  
L.P. Villarreal

2019 ◽  
Vol 208 (3-4) ◽  
pp. 487-494 ◽  
Author(s):  
Ilija Brizić ◽  
Lea Hiršl ◽  
Marko Šustić ◽  
Mijo Golemac ◽  
William J. Britt ◽  
...  

1994 ◽  
Vol 111 (3) ◽  
pp. 259-268 ◽  
Author(s):  
J.E. Greenlee ◽  
S.H. Clawson ◽  
R.C. Phelps ◽  
W.G. Stroop

1976 ◽  
Vol 143 (6) ◽  
pp. 1367-1381 ◽  
Author(s):  
H J Eggers

Echo virus 9- or Coxsackie A 9-infected newborn mice are protected from paralysis and death by combined treatment with nontoxic concentrations of HBB plus guanidine. HBB alone also protects Coxsackie A 9, but not echo virus 9-infected animals, whereas guanidine alone is ineffective in either case. Protection is due to inhibition of virus multiplication via the antiviral activity of these selective inhibitors. Treatment must be begun at the latest 48 h after virus inoculation. 3 days of treatment are sufficient if started at the time of virus inoculation. Failure of protection after treatment with one compound alone is not due to rapid development of drug-resistant virus mutants. Infected, successfully treated mice may develop a solid immunity.


Acta Tropica ◽  
2006 ◽  
Vol 97 (2) ◽  
pp. 126-139 ◽  
Author(s):  
W. Gomes-Leal ◽  
L.C. Martins ◽  
J.A.P. Diniz ◽  
Z.A. Dos Santos ◽  
J.A. Borges ◽  
...  

2007 ◽  
Vol 88 (1) ◽  
pp. 63-73 ◽  
Author(s):  
Lívia C. Martins ◽  
José A. P. Diniz ◽  
Eliana V. P. Silva ◽  
Vera L. R. S. Barros ◽  
Hamilton A. O. Monteiro ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document